MorphoSys’ chief scientist hits the exit, triggering R&D reorganization as they shift focus to US in anticipation of looming FDA approval
Just a few days after opening up its new US headquarters on Boston harbor in prep for what they believe is the imminent approval of a new CAR-T rival, MorphoSys says that its top scientist is stepping down and they’re reorganizing R&D under development chief Malte Peters.
We don’t know the details about what’s up, aside from the fact that they said in an announcement that 17-year company veteran Markus Enzelberger is leaving his job as chief scientific officer to explore new opportunities. And with his departure, they will be “integrating” research into the development operation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.